Experimental vaccine displays potential in type 1 diabetes

06/27/2013 | Reuters

Insulin-treated type 1 diabetes patients who received the experimental vaccine TOL-3021 once weekly showed increased C-peptide levels and attained reductions in T-cell rates, according to a study in Science Translational Medicine. The vaccine also helped preserve some remaining beta cells in patients at 12 weeks without side effects, researchers noted.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA